Announcement of the Dissertation Defense of Doctor of Sciences (DSc) Botirov Ro‘zali Anvarovich

Announcement of the Dissertation Defense of Doctor of Sciences (DSc) Botirov Ro‘zali Anvarovich

I. General Information.

The topic of the dissertation, the cipher of the specialty (the name of the branch of science in which the academic degree is awarded): “Technologies of substances on primary and secondary metabolites of Haplophyllum perforatum, Arundo donax, Capparis spinosa and Stevia rebaudiana plants” 02.00.10-Bioorganic chemistry.

The defense will take place on December 29, 2025 at 09:00 a.m.

The registration number of the thesis topic: В2024.4.PhD/K869.

Scientific Consultant: Doctor of Technical Sciences, Academician Sagdullayev Shamansur Shakhsaidovich.

The name of the institution where the dissertation was performed: S. Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan. The name of the institution where the Scientific council works, the number of the scientific council: S. Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, DSс.02/30.01.2020. К/Т. 104.01.

Official opponents: doctor of technical sciences, professor Sagdullaev Bakhodir Takhirovich, doctor of technical sciences, professor Rakhmanberdiev Goffar Rakhmanberdiyevich, doctor of chemical sciences, professor Gafurov Makhmudjon Bakievich.

Leading organization: Tashkent Pharmaceutical Institute.

II. The aim of the study is developing technologies for the production of medicinal substances and biologically active supplements: Skimmianin (antidepressant) from H.perforatum; Donsumin (tonic) from A.donax; natural sweeteners Sweetlife-I and Sweetlife-II from S.rebaudiana; stachydrine (accelerates blood clotting), Kapparin (a combination of flavonoids, used for the treatment of endometriosis), and Kappaspin -1 (a combination of polysaccharides with analgesic, anti-inflammatory, and antihypoxic effects) from C.spinosa; and Kappaspine (a combination of polysaccharides, used for the prevention of Parkinson's disease) from the buds and unripe fruits of this plant.

III. The scientific novelty of the study is as follows:

determined optimal conditions for the extraction of new biologically active substances based on primary and secondary metabolites from H.perforatum, A.donax, C.spinosa, and S.rebaudiana plants using mathematical experimental design and single-factor experiments;

developed the optimal conditions for the production of a high-purity skimmianin substance with antidepressant properties from H.perforatum extract using liquid-to-liquid technology with a high yield (80%);

determined the optimal conditions for the production of donsumin (a high-purity alkaloid concentration) with tonic properties from A.donax extract using liquid-to-liquid technology (77%);

studied the optimal conditions for the production of substances from the C.spinosa plant: capparin (for the treatment of endometriosis) and stachydrine (for accelerating blood clotting) from the extract using precipitation and sorption methods; as well as cappaspine-1 (with analgesic, anti-inflammatory, and antihypoxic effects) from an aqueous extract of plant meal;

developed analytical methods using chromatograph spectrophotometry and HPLC enabling step-by-step control of the production stages of medicinal and dietary supplement substances;

for the first time in the Republic developed a technology for the production of natural sweeteners and sugar substitutes Sweetlife-I and Sweetlife-II from the extract of the cultivated S. rebaudiana plant using a liquid purification method;

installed at the Institute's Pilot manufacture the facilities for production of Skimmianin, Donsumin, Stachydrin, Kapparin, Kappaspin-1, Kappaspin, Sweetlife-I, and Sweetlife-II substances, and the production technologies for the substances revised. These facilities were used to produce primary standard samples of the substances for studying their pharmacological and toxicological activity, as well as for developing drafts of the necessary regulatory and technical documentation.

Technical specifications (TS) and technological instructions (TI) have been developed and approved by higher-level organizations.

IV. Implementation of research results. Based on the results of scientific research on the development of production technologies for substances from the test subjects:

A patent for a method for producing the medicinal product Skimmianin from raw materials was received from the Intellectual Property Agency of the Republic of Uzbekistan (No. IAP 7879, 2024). The possibility of developing a new antidepressant drug was created;

A patent for the medicinal product Donsumin which has a tonic effect, was received from the Intellectual Property Agency of the Republic of Uzbekistan (IAP No. 7678, 2024). This created the way for the development of a new tonic medicinal product.

A patent for the medicinal product Kappaspin for the prevention of Parkinson's disease was received from the Intellectual Property Agency of the Republic of Uzbekistan (IAP 8162, 2025). This opened the possibility for the development of a new medicinal product for the prevention of Parkinson's disease.

A patent for a method for producing the natural sweeteners Sweetlife-I and Sweetlife-II (IAP 8305, 2025) was received from the Intellectual Property Agency of the Republic of Uzbekistan. This opened the way for their use in the food industry as low-calorie sweeteners.

Organization standards (Ts 03535440-041:2021, Ts 03535440-045:2021) and technological instructions (TI 03535440-042:2021, TI 03535440-042:2022) have been developed for Sweetlife-I and Sweetlife-II. Serial production of Sweetlife-I and Sweetlife-II has been implemented.

Organization standards (Ts 03535440-045:2021) and technological instructions (TI 03535440-049:2022) have been developed for the Kappaspin substance, creating the possibility of introducing a substance with anti-inflammatory and analgesic properties into practice.

An organizational standard and technological instructions (TI 03535440-073:2025) for the substance were developed. The possibility of introducing a dietary supplement against endometriosis into practice was created.

Print